About Us

Overview

Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. As a leading orphan endocrine disease company, we create distinct and transformative treatments for a wide range of endocrine diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed as a potential treatment for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: classic congenital adrenal hyperplasia (CAH) and endogenous Cushing’s syndrome (CS).